Browse articles from EyeWorld.org related to presbyopia. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ FDA approves aceclidine-based drop for presbyopia ➤ Long-term data supports efficacy of continuous wet AMD treatment ➤ First patient dosed in trial for drug eluting lacrimal canaliculus plug ➤ Acquisition news ➤ ASCRS news and events
➤ Results from second Phase 3 pivotal trial for presbyopia drop ➤ Interim Phase 2 data presented on DME, wet AMD treatment ➤ Phase 2 trial to investigate oral DME treatment ➤ First patient dosed in investigational cell therapy for photoreceptor diseases ➤ Phase 1 trial begins for minimally invasive dry AMD treatment ➤ Acquisitions and other company news ➤ ASCRS news and events
➤ FDA approves first-in-class DED drop ➤ FDA accepts NDA for topical presbyopia therapy ➤ TFOS DEWS III ➤ Topline results in Phase 3 study evaluating night driving impairment after keratorefractive surgery ➤ IND application submitted for pediatric myopia treatment ➤ Study sheds light on clinical inherited retinal diseases without genetic mutations ➤ ASCRS news and events
➤ NDA submitted to the FDA for presbyopia drop ➤ FDA issues complete response letter to dry eye NDA ➤ FDA accepts BLA resubmission for bevacizumab to treat wet AMD ➤ One-month results in Phase 1/2 trial for treating Leber congenital amaurosis in a pediatric patient ➤ ASCRS news and events
➤ ASCRS EyeWorld Weekly: View the current issue ➤ Transepithelial crosslinking NDA submission accepted ➤ Fast Track designation granted to drop being investigated for night driving impairment due to visual disturbances ➤ First-in-human interventional study for gene therapy treating Leber congenital amaurosis 4 ➤ Positive outcomes observed for geographic atrophy drug ➤ Regenerative Medicine Advanced Therapy designation granted to stem cell therapy for dry AMD ➤ ASCRS news and events
➤ Topline Phase 3 pivotal study for BRIMOCHOL for treatment of presbyopia ➤ Positive Phase 2b/3 results for oral treatment of thyroid eye disease ➤ Clinical plan for first-in-human trial for investigational dry AMD therapy ➤ Update on registrational program therapy targeting various retinal diseases ➤ Collaboration to develop RNAi program targeting geographic atrophy ➤ ASCRS news and events
➤ Topline Phase 3 results for sublingual, opioid-free sedation ➤ Phase 1 results for non-surgical cell therapy for corneal edema ➤ First Phase 2 study evaluates wet AMD gene therapy in both eyes of patients ➤ Update on Phase 3 study evaluating treatment for progressive myopia ➤ FDA to review NDA for first-in-class dry eye treatment ➤ Enrollment complete for Phase 1/2 study evaluating novel IOP-lowering drug delivery platform ➤ ASCRS news and events
➤ Positive topline Phase 3 data for presbyopia drop ➤ Topline results for oral therapy targeting geographic atrophy ➤ Positive topline results from Phase 2 sustained-delivery drug for DME ➤ Study assesses new virtual reality simulator for phaco ➤ ASCRS news and events
➤ Whole-eye transplant 1 year later ➤ Phase 3 trial investigating new presbyopia drop therapy begins ➤ Study reports on multi-interventional glaucoma technique ➤ Topline results from Phase 3 trial for drug for active thyroid eye disease ➤ Pilot study complete for AMD treatment ➤ ASCRS news and events